LAGANA', ALESSANDRO
LAGANA', ALESSANDRO
DIPARTIMENTO DI MEDICINA MOLECOLARE
A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC)
2025 Laganà, Alessandro; Ielo, Claudia; Buffolino, Sonia; Di Lascio, Attilio; Bizzoni, Luisa; Scalzulli, Emilia; Carmosino, Ida; Bisegna, MARIA LAURA; Diverio, Daniela; Breccia, Massimo
Asciminib as a third line option in chronic myeloid leukemia
2023 Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Martelli, Maurizio; Breccia, Massimo
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib
2025 Laganà, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Sorella, S.; Ielo, C.; Zhdanovskaya, N.; Martelli, M.; Breccia, M.
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut -AML): a flow-cytometric marker for an accurate diagnostic workup
2025 Laganà, Alessandro; Kasmi, Deborah; Diverio, Daniela; Bisegna, MARIA LAURA; Carmosino, Ida; Scalzulli, Emilia; Minotti, Clara; Laura Milani, Maria; Buffolino, Sonia; Martelli, Maurizio; Breccia, Massimo; DE PROPRIS, Maria Stefania
Direct oral Anticoagulants (DOACs) in the Onco-Hematologic Patients
2025 Biglietto, M.; Ligia, S.; Lagana, A.; Assanto, G. M.; Gherardini, M.; Baldacci, E.; Santoro, C.; Chistolini, A.
Evaluation of VTE-PREDICT Risk Score in Patients Receiving Low-Dose DOACs for Venous Thromboembolism (VTE) Secondary Prophylaxis
2024 Laganà, Alessandro; Assanto, Giovanni Manfredi; Passucci, Mauro; Santoro, Cristina; Chistolini, Antonio
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
2024 Lagana, Alessandro; Passucci, Mauro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Costa, Alessandro; Bisegna, Maria Laura; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors
2022 Breccia, Massimo; Assanto, Giovanni Manfredi; Laganà, Alessandro; Scalzulli, Emilia; Martelli, Maurizio
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission
2023 Laganà, Alessandro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Passucci, Mauro; Ielo, Claudia; Costa, Alessandro; Masucci, Chiara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
2025 Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria L.; Martelli, Maurizio; Breccia, Massimo
Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic
2022 Laganà, Alessandro; Ferri, Gianluca; Passucci, Mauro; Salvatori, Martina; Bisegna, MARIA LAURA; Paoletti, Francesca; Aji, Francesco; Breccia, Massimo; Antonio Brunetti, Gregorio; Morano, Salvatore Giacomo; Annechini, Giorgia; Carmosino, Ida; Martelli, Maurizio; Girmenia, Corrado
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up
2024 Laganà, Alessandro; Assanto, Giovanni Manfredi; Masucci, Chiara; Passucci, Mauro; Donzelli, Livia; Serrao, Alessandra; Baldacci, Erminia; Santoro, Cristina; Chistolini, Antonio
T-cell Receptor (TCR)-Vβ Repertoire Flow Cytometry for T-cell Lymphoproliferative Disorder: a Retrospective Analysis of a Single-Center Real-Life Laboratory Experience
2025 Antonacci, M.; Micozzi, J.; Costa, A.; Lagana, A.; Milani, M. L.; Intoppa, S.; Bellomarino, V.; Nardacci, M. G.; Biglietto, M.; Imperatore, S.; Bisegna, M. L.; Martelli, M.; Starza, I. D.; De Propris, M. S.
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety
2024 Lagana, Alessandro; Scalzulli, Emilia; Bisegna, Maria Laura; Carmosino, Ida; Ielo, Claudia; Costa, Alessandro; Torrieri, Lorenzo; Totaro, Matteo; Martelli, Maurizio; Breccia, Massimo
Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience
2024 Laganà, Alessandro; Fucci, Ludovica; Sorella, Silvia; Santoro, Cristina; Chistolini, Antonio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC) | 2025 | Laganà, Alessandro; Ielo, Claudia; Buffolino, Sonia; Di Lascio, Attilio; Bizzoni, Luisa; Scalzulli, Emilia; Carmosino, Ida; Bisegna, MARIA LAURA; Diverio, Daniela; Breccia, Massimo | |
| Asciminib as a third line option in chronic myeloid leukemia | 2023 | Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Martelli, Maurizio; Breccia, Massimo | |
| Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib | 2025 | Laganà, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Sorella, S.; Ielo, C.; Zhdanovskaya, N.; Martelli, M.; Breccia, M. | |
| CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut -AML): a flow-cytometric marker for an accurate diagnostic workup | 2025 | Laganà, Alessandro; Kasmi, Deborah; Diverio, Daniela; Bisegna, MARIA LAURA; Carmosino, Ida; Scalzulli, Emilia; Minotti, Clara; Laura Milani, Maria; Buffolino, Sonia; Martelli, Maurizio; Breccia, Massimo; DE PROPRIS, Maria Stefania | |
| Direct oral Anticoagulants (DOACs) in the Onco-Hematologic Patients | 2025 | Biglietto, M.; Ligia, S.; Lagana, A.; Assanto, G. M.; Gherardini, M.; Baldacci, E.; Santoro, C.; Chistolini, A. | |
| Evaluation of VTE-PREDICT Risk Score in Patients Receiving Low-Dose DOACs for Venous Thromboembolism (VTE) Secondary Prophylaxis | 2024 | Laganà, Alessandro; Assanto, Giovanni Manfredi; Passucci, Mauro; Santoro, Cristina; Chistolini, Antonio | |
| Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation | 2024 | Lagana, Alessandro; Passucci, Mauro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Costa, Alessandro; Bisegna, Maria Laura; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo | |
| Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors | 2022 | Breccia, Massimo; Assanto, Giovanni Manfredi; Laganà, Alessandro; Scalzulli, Emilia; Martelli, Maurizio | |
| One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission | 2023 | Laganà, Alessandro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Passucci, Mauro; Ielo, Claudia; Costa, Alessandro; Masucci, Chiara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo | |
| Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib | 2025 | Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria L.; Martelli, Maurizio; Breccia, Massimo | |
| Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic | 2022 | Laganà, Alessandro; Ferri, Gianluca; Passucci, Mauro; Salvatori, Martina; Bisegna, MARIA LAURA; Paoletti, Francesca; Aji, Francesco; Breccia, Massimo; Antonio Brunetti, Gregorio; Morano, Salvatore Giacomo; Annechini, Giorgia; Carmosino, Ida; Martelli, Maurizio; Girmenia, Corrado | |
| Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up | 2024 | Laganà, Alessandro; Assanto, Giovanni Manfredi; Masucci, Chiara; Passucci, Mauro; Donzelli, Livia; Serrao, Alessandra; Baldacci, Erminia; Santoro, Cristina; Chistolini, Antonio | |
| T-cell Receptor (TCR)-Vβ Repertoire Flow Cytometry for T-cell Lymphoproliferative Disorder: a Retrospective Analysis of a Single-Center Real-Life Laboratory Experience | 2025 | Antonacci, M.; Micozzi, J.; Costa, A.; Lagana, A.; Milani, M. L.; Intoppa, S.; Bellomarino, V.; Nardacci, M. G.; Biglietto, M.; Imperatore, S.; Bisegna, M. L.; Martelli, M.; Starza, I. D.; De Propris, M. S. | |
| Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety | 2024 | Lagana, Alessandro; Scalzulli, Emilia; Bisegna, Maria Laura; Carmosino, Ida; Ielo, Claudia; Costa, Alessandro; Torrieri, Lorenzo; Totaro, Matteo; Martelli, Maurizio; Breccia, Massimo | |
| Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience | 2024 | Laganà, Alessandro; Fucci, Ludovica; Sorella, Silvia; Santoro, Cristina; Chistolini, Antonio |